La Jolla Institute for Allergy and Immunology

Centre National De La Recherche Scientifique

Universitè De Montpellier

Université Pierre Et Marie Curie

Receptos, Inc.

Marcos Steinberg

Carl F Ware

Timothy C Cheung

David Klatzmann

Adam Richard Yeager

Junko Tamiya

Lin Zhang

Michael Croft

Naomi Taylor

Junhua Fan

Gilles Marodon

Philip Turnbull

Cedric Mongellaz

Carl De Trez

Raffaele Pasceri

Naomi Sitbon

Oumeya Adjali

Maria Ieva

Chantal Jacquet

Kevan Grant

Ian R Humphreys

Karen G Potter

Yang Tran

Christopher A Benedict

Tom Fowler

Mitchell Kronenberg

Hanae Benelkebir

Compounds are provided having the structure of the following Formula I: where R, R, R, Rand Rare as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

CXCR3 receptor agonists

The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., LIGHT polypeptide sequence) that bind to the HVEM cis complexes.

Methods of modulating HVEM, BTLA and CD160 cis complex response or signaling activity with soluble light polypeptide sequences

The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., antibodies) that bind to the HVEM cis complexes.

HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use

The invention relates to the use of viral vectors able to stably integrate into the genome of thymic stromal cells, or of intrathymic lymphocytes or lymphocytes precursors, for the manufacture of a medicine intended for intrathymic administration in the frame of the prevention or treatment of genetic immunodeficiencies, acquired immunodeficiencies, or for the induction of immune tolerance of the organism to self or non-self gene products, cells or tissues, or for the prevention or treatment of autoimmune diseases.

Treating immunodeficiencies by intrathymic injection of nucleotide sequences

Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.

Compositions and methods for modulating responses mediated or associated with BTLA activity

Growing community of inventors

San Diego, CA, United States of America

Marcos Steinberg